Phase 1 Study Of PF-06863135, A BCMA- CD3 Bispecific Antibody, In Relapse/ Refractory Multiple Myeloma


The purpose of this trial is to assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

SparkCures ID 930
Trial Phase Phase 1
Enrollment 80 Patients
Trial Sponsors
  • Pfizer
NCT Identifier


Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Patients with relapse/ refractory multiple myeloma
  • Performance Status of 0- 2 (unless due to bone pain)
  • Adequate bone marrow, kidney and liver function

Exclusion Criteria:

  • History of active autoimmune disorders
  • Active and clinically significant bacterial, fungal, or viral infection
  • Major surgery within 4 weeks of study treatment start
  • Radiation therapy within 2 weeks of study treatment start
  • Less than 30 days since last dose of anti CD38 therapy or less than 5 half-lives since last dose of previous systemic therapy.
  • Stem cell transplant (autologous or allogeneic) within 100 days of study treatment start

US Trial Locations

Accepting Patients

The following is a listing of trial locations that are open and accepting patients.

New York
North Carolina


There are no resources, links or videos to display for this clinical trial.